Value proposition

Leveraging science and innovation to accelerate the development of next-generation antibody therapeutics.

AAX Biotech AB is a biotech company spun out from Karolinska Institutet by co-founders Mats AA Persson and Daniel X Johansson. We specialize in next-generation antibody therapeutics through our two unique and proprietary technologies, SeqitopeTM and Opti-mAbTM, that enable high-resolution and high throughput epitope mapping as well as stabilization of single chain variable fragments (scFv) for applications such as bispecific antibodies and CAR-T cells.

Our team is made up of highly qualified experts, all with PhDs in relevant fields. Our mission is to innovate and solve unmet needs in antibody-based medicine development. We aim to be a leading partner for the global biopharmaceutical industry focusing on a broad range of diseases including cancer, autoimmune disorders, and neurological conditions. We are committed to providing unparalleled expertise and innovative technologies that contribute to the advancement of novel antibody therapeutics.

Technologies:
SeqitopeTM is a high-resolution, high throughput method for antibody epitope mapping that accelerates the development of efficacious therapeutics.

Opti-mAbTM is a new scFv format with dramatically improved expression levels and reduced aggregation tendencies. This will significantly improve the next generation of cutting-edge immunotherapies such as CAR-T and bispecific antibodies.

biotech, antibody therapeutics, next-generation antibody therapeutics, antibody-based medicines, drug development, cancer therapy, autoimmune diseases, neurological diseases, big pharma, and biopharmaceutical industry